Rezolute, Inc. (RZLT)
NASDAQ:RZLT
Want to see RZLT full AI Analyst Report?
RZLT Stock Chart & Stats
$3.46
-$0.34(-6.35%)
At close: 4:00 PM EST
$3.46
-$0.34(-6.35%)
Day’s Range― - ―
52-Week Range$1.07 - $11.46
Previous CloseN/A
Volume107.87K
Average Volume (3M)1.67M
Market Cap
$416.95M
Enterprise Value$429.93M
Total Cash (Recent Filing)$120.27M
Total Debt (Recent Filing)$1.11M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Sep 10, 2026EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding96,292,330
10 Day Avg. Volume2,610,965
30 Day Avg. Volume1,669,166
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.09
Price to Sales (P/S)0.00
P/FCF Ratio-4.91
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.69K
Enterprise Value/Ebitda-5.28
Forecast
1Y Price Target
$8.83Price Target Upside155.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.7
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetVery low reported debt (debt-to-equity ~0.01) materially reduces near-term refinancing pressure and preserves optionality for clinical programs. For a cash-burning clinical-stage biotech this structural conservatism lowers bankruptcy risk and improves ability to negotiate partnerships or staged financing over the next several quarters.
Positive Interim Phase 3 UpLIFT Efficacy And SafetyInterim upLIFT results showing majority of enrollees achieving at least 50% IV glucose reduction and no drug-related adverse events materially de-risk ersodetug's tumor-HI program. Durable evidence of efficacy and tolerability increases probability of regulatory success in that indication and supports long-term clinical value and partner interest.
Constructive FDA Engagement On SunRIZE ProgramRegulator willingness to review a comprehensive submission after recognizing endpoint and behavioral confounders is a structural positive. It creates a defined regulatory path short of immediate rejection, enabling the company to potentially obtain approval based on aggregated data and analyses rather than requiring wholly new pivotal trials, lowering long-term binary risk.
Bears Say
Pre-revenue With Widening Net LossesPersistent lack of product revenue and materially widening losses indicate the company remains fully development-stage. Continued operating losses deplete equity and require external capital, constraining strategic flexibility. Over months this increases dilution risk, pressures program timelines, and limits investments outside core trials.
Weak Cash Generation And Accelerating Free Cash Flow BurnHeavy and accelerating cash burn undermines runway absent new financing or partnerships. Reliance on equity financings or milestones is structurally dilutive and can force prioritization of programs. Over 2–6 months, this pressure can delay studies, reduce bargaining power with potential partners, or necessitate asset sales or licensing.
Regulatory Uncertainty After SunRIZE Missed Primary EndpointA pivotal trial missing its primary endpoint creates structural regulatory and commercial uncertainty. Even with FDA dialogue, the need for comprehensive review or additional data increases time and cost to approval, raising the likelihood of additional studies or label limits. That uncertainty materially affects long-term commercialization prospects.
Rezolute News
RZLT FAQ
What was Rezolute, Inc.’s price range in the past 12 months?
Rezolute, Inc. lowest stock price was $1.07 and its highest was $11.46 in the past 12 months.
What is Rezolute, Inc.’s market cap?
Rezolute, Inc.’s market cap is $416.95M.
When is Rezolute, Inc.’s upcoming earnings report date?
Rezolute, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 85 days.
How were Rezolute, Inc.’s earnings last quarter?
Rezolute, Inc. released its earnings results on May 12, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.181 by $0.021.
Is Rezolute, Inc. overvalued?
According to Wall Street analysts Rezolute, Inc.’s price is currently Undervalued.
Does Rezolute, Inc. pay dividends?
Rezolute, Inc. does not currently pay dividends.
What is Rezolute, Inc.’s EPS estimate?
Rezolute, Inc.’s EPS estimate is -0.15.
How many shares outstanding does Rezolute, Inc. have?
Rezolute, Inc. has 96,292,330 shares outstanding.
What happened to Rezolute, Inc.’s price movement after its last earnings report?
Rezolute, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.181. Following the earnings report the stock price went up 0.909%.
Which hedge fund is a major shareholder of Rezolute, Inc.?
Currently, no hedge funds are holding shares in RZLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rezolute Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.83 (155.30% Upside)
$8.83 (155.30% Upside)
Blogger Sentiment
Neutral
RZLT Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 137.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.09%
12-Months-Change
Fundamentals
Return on Equity
-58.82%
Trailing 12-Months
Asset Growth
32.43%
Trailing 12-Months
Company Description
Rezolute, Inc.
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies for metabolic conditions marked by persistent glucose imbalances, primarily serving the United States market. Its flagship product candidate, RZ358, a human monoclonal antibody, is currently progressing through Phase 2b clinical trials as a potential treatment for congenital hyperinsulinism, an exceptionally rare genetic disorder impacting pediatric patients. The company is also developing RZ402, a powerful and selective plasma kallikrein inhibitor, which is in Phase 1 clinical evaluation for the ongoing management of diabetic macular edema. Founded in 2010, the entity was formerly known as AntriaBio, Inc. before adopting the Rezolute, Inc. name in December 2017, and its operations are based out of Redwood City, California.
RZLT Stock 12 Month Forecast
Average Price Target
$8.83
▲(155.30% Upside)
Technical Analysis
Ownership Overview
10.88% Insiders
32.67% Mutual Funds
33.54% Other Institutional Investors
14.10% Public Companies and
Individual Investors